{'fraction_non_alphanumeric': 0.029442691903259727, 'fraction_numerical': 0.008412197686645636, 'mean_word_length': 5.476190476190476, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Trifluridine / tipiracil (FTd / TPI, TAS-102) in the treatment of patients with metastatic colon cancer: from preclinical experiments to routine clinical practice

The development of new treatment options gradually brings metastatic colon cancer closer to a chronic disease that can last for years. One of such options is trifluridine / tipiracil (FTD / TPI, TAS-102), a new chemotherapeutic agent, which has already been registered in more than 60 countries. It increases patients’ survival and has an acceptable toxicity profile (adverse events primarily include hematological complications). This literature review aims to cover various aspects related to this new drug, including its pharmacokinetics, maximum tole rated dose, possibility of its use in patients with liver disorders, results of its simultaneous use with targeted therapy, comparison with other therapeutic approaches in patients with chemorefractory metastatic rectal cancer, etc.